The multi-biomarker disease activity (MBDA) score, calculated from the concentrations of 12 serum biomarkers, is an objective validated disease activity measure for patients with RA. It has been shown to track disease activity in patients with early and established RA, treatment-naïve or not, and to associate with risk of radiographic progression. 8 Here we investigated whether the MBDA score might inform RA diagnosis in patients with UA.
We evaluated 126 patients from the prospective Synoviomics cohort 9 ; 81 fulfilled ACR/EULAR 2010 criteria for RA and 45 for UA. 1 4 At study entry, all patients had ≥1 swollen joint, <1 year of clinical symptoms, and were naïve to diseasemodifying antirheumatic drugs and corticosteroids. Following baseline clinical assessment and serum collection, patients were treated according to EULAR guidelines. Patients were grouped as UA-UA (n=29), UA-RA (n=16) or RA-RA (n=81) based on their fulfilment of ACR/EULAR 2010 classification criteria for RA at baseline and after 2 years.
Baseline MBDA score, DAS28, joint counts, acute phase protein concentrations and autoantibody status differed significantly between patient with UA and RA ( p<0.005) (table 1). Significant correlations ( p<0.001) were observed between baseline MBDA score and DAS28 (r=0.62), erythrocyte sedimentation rate (ESR) (r=0.67), and C reactive protein (CRP) (r=0.84) in the overall population and separately in the RA (r=0.57; 0.59; 0.83) and UA (r=0.63; 0.70; 0.82) groups.
To test whether baseline MBDA score or other disease activity measures were associated with fulfilment of RA classification criteria after 2 years, trends across the three groups (RA-RA, UA-RA and UA-UA) were evaluated using Jonckheere-Terpstra test. Statistically significant ( p<0.05) decreasing trends were observed for all measurements tested (figure 1). Pairwise comparisons by Wilcoxon's rank-sum test showed that baseline disease activity score based on 28 joints, ESR, CRP, swollen joint count based on 66 joints, tender joint count based on 68 joints (TJC68) and MBDA score were significantly greater in patients with RA-RA versus UA-RA ( p<0.01). MBDA score was not significantly different between UA-RA versus UA-UA ( p=0.132). Only baseline TJC68 was significantly greater in UA-RA versus UA-UA (median (IQR): 5 (1-7.25) versus 1 (1-3), p=0.010); this difference remained statistically significant after adjustment for multiple testing ( p=0.019). 10 Female gender was also associated with UA-RA (14/16) versus UA-UA (13/29) ( p=0.005).
In summary, baseline MBDA score did not inform fulfilment of RA classification criteria in patients with UA. However, consistent with MBDA score measuring active disease in patients with RA, baseline MBDA scores were higher in patients with an initial RA diagnosis compared with UA. Limitations to be considered include the relatively small number of patients with UA-RA and possible treatment effect on disease course in patients with UA. 
